Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial. .
The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells